Suppression of chronic experimental autoimmune neuritis by nasally administered recombinant rat interleukin-6

Immunology

Volumn 97, Issue 1, 1999, Pages 69-76

  Deretzi, G ^a   Pelidou, S H ^a   Zou, L P ^a   Quiding, C ^a   Mix, E ^c   Levi, M ^b   Wahren, B ^b   Zhu, Jie ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRANASAL DRUG ADMINISTRATION; MALE; NEURITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE;

ADMINISTRATION, INTRANASAL; ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INTERLEUKIN-6; MALE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; SCIATIC NERVE; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032949734     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00749.x     Document Type: Article

References (45)

1. 1. Fearon E.R., Pardoll D.M., Itala T. et al. (1990) Interleukin 2 production by tumor cells bypasses T helpers function in the generation of an anti-tumor response. Cell 60, 397.
2. 2. Mentzel B. & Wraith D.C. (1993) Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 5, 1159.
3. 3. Xiao B.G., Bai X.F., Zhang G.X. & Link H. (1998) Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol 84, 230.
4. 4. Hirano T., Yasukawa K., Harada H. et al. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73.
5. 5. Hirano T. (1994) Interleukin 6. In: The Cytokine Handbook (ed. A. W. Thomson), 2nd edn, p. 145. London: Academic Press.
6. 6. Hirano T. (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16, 249.
7. 7. Barton B. (1997) Molecule of the month. IL-6: Insights into the novel biological activities. Clin Immunol Immunophathol 85, 16.
8. 8. Wong G.W. & Clark S.C. (1988) Multiple actions of interleukin 6 within a cytokine network. Immunol Today 9, 137.
9. 9. Zhu J., Mix E. & Link H. (1998) Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain Barré syndrome. J Neuroimmunol 84, 40.
10. 10. Weller M., Stevens A., Sommer N., Melms A., Dichans J. & Witholter H. (1991) Comparative analysis of cytokine patterns in immunological disorders. J Neurol Sci 104, 215.
11. 11. Sivieri S., Ferrerini A.M., Lolli F. et al. (1997) Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci 147, 93.
12. 12. Strassmann G., Fong M., Windsor S. & Neta R. (1993) The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 5, 285.
13. 13. Baumann H. & Gauldie J. (1994) The acute response. Immunol Today 15, 74.
14. 14. Fattori E., Cappelletti M., Costa P. et al. (1994) Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180, 1243.
15. 15. Rodriguez M., Pavelco K.D., Mckinney C.W. & Leibowitz J.L. (1994) Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 153, 3811.
16. 16. Tilg H., Dinarello C.A. & Mier J. (1997) IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18, 428.
17. + T cells. J Exp Med 185, 461.
18. 18. Mizuhara H., O'neil E., Seki N. et al. (1994) T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin-6. J Exp Med 179, 1529.
19. 19. Aderka D., Le J. & Vilcek J. (1989) IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor-α production in cultured human monocytes, U937 cells and in mice. J Immunol 143, 3517.
20. 20. Waksman N.H. & Adams R.D. (1955) Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvant. J Exp Med 102, 213.
21. 21. Kaldubowski M. & Hughes R.A. (1979) Identification of the neuritogen for experimental allergic neuritis. Nature 277, 140.
22. 22. Milner P.A., Lovelidge C.A., Taylor W.A. & Hughes R.A. (1987) P0 myelin protein produces experimental allergic neuritis. J Neurol Sci 79, 275.
23. 23. Olee T., Powell H.C. & Brostoff S.W. (1990) New minimum length requirement for a T cell epitope for experimental allergic neuritis. J Neuroimmunol 27, 187.
24. 24. Hanh A.F. (1996) Experimental allergic neuritis as a model for the immune-mediated demyelinating neurophathies. Rev Neurol 152, 328.
25. 25. Hanh A.F., Feasby T.E., Steele A., Lovgren D.S. & Berry J. (1988) Demyelination and axonal degeneration in Lewis rat experimental allergic neuritis depend on the myelin dosage. Lab Invest 59, 115.
26. 26. Harvey G.K., Polland J.D., Schindhelm K. & Antony J. (1987) Experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci 81, 215.
27. 27. Adams A.M., Atkinson P.F., HALL S.M., Hughes R.A. & Taylor W.A. (1989) Chronic experimental allergic neuritis in Lewis rats. Neuropathol Appl Neurobiol 15, 249.
28. 28. Rostami A., Gregorian S.K., Brown M.J. & Pleasure D.E. (1990) Induction of severe experimental allergic neuritis with a synthetic peptide corresponding to the 53 amino acid sequence of the myelin P2 protein. J Neuroimmunol 30, 145.
29. 29. Said G. & Hontebeyrie-Jockowicz M. (1992) Nerve lesions induced by macrophage activation. Res Immunol 143, 589.
30. 30. Bakhiet M., Diab A., Mustafa M., Zhu J., Lindqvist L. & Link H. (1997) Potential role of autoantibodies in the regulation of cytokine responses during bacterial infections. Infect Immun 65, 3300.
31. 31. Gubels K., Brocke S., Abrams J. & Steiman L. (1995) Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated level of IL-6 bioactivity in central nervous system and circulation. Mol Med 1, 795.
32. 32. Kammuller M. & Ryffel B. (1997) Extrapolation of experimental safety data to humans: the interleukin-6 case. Clin Immunol Immunopathol 83, 15.
33. 33. Schindler R., Mancilla J., Enders S., Ghorbani R., Clark S.C. & Dinarello C.A. (1990) Correlations and interactions in the production of IL-6, tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75, 40.
34. 34. Baumann H. & Strassmann G. (1993) Suramin inhibits the stimulation of acute phase protein genes by IL-6-type cytokines in rat hepatoma cells. J Immunol 151, 1456.
35. 35. Salas M.A., Evans S.W., Levell M.J. & Whicher J.T. (1990) Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 79, 470.
36. 36. Besedovsky H., Del Rey A., Sorkin E. & Dinarello C.A. (1986) Immunoregulatory feedback between interleukin-1 and glucocorticosteroid hormones. Science 233, 652.
37. 37. Muraguchi A., Hirano T., Tang B. et al. (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167, 332.
38. 38. Hartung H.P. & Toyka K.V. (1990) T cell and macrophage activation in experimental autoimmune neuritis and Guillain Barré syndrome. Ann Neurol 27 (Suppl.), S 57.
39. 39. Hartung H.P., Kiefer R., Cold R. & Toyka K. (1996) Autoimmunity in the peripheral nervous system. Baillière's Clin Neurol 5, 1.
40. 40. Spies J.M., Pollard J.D., Westald K.W., Bonner J.G. & McLeod J. (1995) Synergy between antibody and P2-reactive T cells in experimental autoimmune neuritis. J Neurol 57, 77.
41. 41. Spies J.M., Westald K.W., Bonner J.G. & Pollard J.D. (1995) Intraneural activated T cells cause focal breakdown of the blood nerve barrier. Brain 118, 857.
42. 42. Redford E.J., Hall S.M. & Smith K.J. (1995) Vascular changes and demyelination induced by the intraneural injection of tumor necrosis factor. Brain 118, 869.
43. 43. Dinarello C. & Wolff S. (1993) The role of interleukin-1 in disease. N Engl J Med 118, 869.
44. 44. Mihara M., Ikuta M., Koishihara Y. & Ohsugi Y. (1991) Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol 21, 2327.
45. 45. Sharjef M.K., Ingmar D.A. & Swash M. (1997) Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain Barré syndrome. Ann Neurol 42, 68.